EQT Life Sciences joins Vaderis Therapeutics’ USD 152 million Series B round with USD 17.5 million investment

EQT Life Sciences invested USD 17.5 million in Vaderis Therapeutics' USD 152 million Series B financing round. The Swiss clinical-stage biotech will use the proceeds to fund Phase 3 development of its lead asset, engasertib, for hereditary hemorrhagic telangiectasia, a rare vascular disease with no approved therapies.

EQT AB invested USD 17.5 million in Vaderis Therapeutics’ USD 152 million Series B financing through an EQT Life Sciences-managed fund. * Vaderis is a Swiss clinical-stage biotech developing targeted therapies for rare vascular diseases. * Proceeds will fund Phase 3 development of lead asset engasertib for hereditary hemorrhagic telangiectasia, a rare inherited blood vessel disorder with no approved therapies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EQT AB published the original content used to generate this news brief on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here